What is Pathmaker Neurosystems?
Pathmaker Neurosystems operates as a clinical-stage enterprise dedicated to the development of non-invasive neuromodulation devices. The company is primarily focused on addressing the unmet medical needs of patients suffering from Amyotrophic Lateral Sclerosis (ALS) and other severe neurological disorders. By leveraging multi-site direct current stimulation technology, Pathmaker aims to suppress neuronal hyperexcitability and facilitate the activation of protein degradation pathways. This innovative approach is designed to restore damaged neural pathways and mitigate protein aggregation in motor neurons, effectively positioning the company at the vanguard of a transformative treatment paradigm within the neuro-tech landscape.
How much funding has Pathmaker Neurosystems raised?
Pathmaker Neurosystems has raised a total of $2.2M across 2 funding rounds:
Debt
$36K
Other Financing Round
$2.2M
Debt (2021): $36K with participation from PPP
Other Financing Round (2024): $2.2M, investors not publicly disclosed
Key Investors in Pathmaker Neurosystems
Undisclosed Investor
Undisclosed investor participating in the funding round.
PPP
Public-Private Partnership
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Pathmaker Neurosystems?
With the successful acquisition of this latest capital, Pathmaker Neurosystems is well-positioned to accelerate its clinical trial roadmap and scale its commercialization efforts. The strategic focus will likely shift toward expanding the application of its neuromodulation technology across a broader spectrum of neurological indications. By prioritizing the validation of its non-invasive devices through rigorous clinical studies, the company is poised to disrupt traditional treatment models. Future growth will depend on the successful translation of its pre-clinical findings into scalable, regulatory-approved medical products that offer tangible improvements in patient outcomes for those battling neurodegenerative diseases.
See full Pathmaker Neurosystems company page
